AbilityPharma Secures Funding of €7M for Progressing Phase 2b Trials of ABTL0812, an Autophagy-Stimulating Drug, in Treating Spread-Out Pancreatic Cancer.

Ranok Therapeutics broadens its clinical trials for its BRD4 protein degradation agent RNK05047, now including tests in China.

ASLAN Pharmaceuticals Offers Update on TREK-DX Research and Emphasizes Eblasakimab's Effectiveness for Patients with Atopic Dermatitis Previously Treated with Dupilumab.

MoonLake reveals notable advancements using Nanobody® sonelokimab over a six-month period for treating active psoriatic arthritis (PsA), along with other crucial updates during its research and development event.

Latest findings from the second phase of testing indicate that amlitelimab may be a top-performing contender for sustained treatment effectiveness in managing eczema.

RemeGen Showcases Study of Unique Disitamab Vedotin (RC48) in Treating Cervical Cancer through Verbal Presentation at 2024 ESGO Event.

Sensorion Reveals Achievement of Main Goal in Phase 2a Trial of SENS-401 for Preserving Remaining Hearing Function.

Celltrion USA has finalized their application for a biologic license to the U.S. Food and Drug Administration for CT-P39, their alternative biosimilar to XOLAIR (omalizumab).

Wegovy® receives green light in the USA to diminish heart-related health hazards for those excessively heavy or with obesity coupled with confirmed heart conditions.

BeiGene, Ltd., a global oncology-focused biopharma, announced FDA's fast-track approval for its cancer drug BRUKINSA(zanubrutinib).

Eli Lilly and Company announced that the FDA will convene its Advisory Committee to discuss Phase 3 results of the TRAILBLAZER-ALZ 2 study on the efficacy and safety of donanemab in early Alzheimer's.

Regor Therapeutics Group has announced the launch of its Phase 2 trial on RGT-075, an oral, highly selective GLP-1 receptor agonist.